MAPT and Alzheimer disease: The core Alzheimer’s disease pathology group, as defined from the entire cohort, included neuroimaging and fluid biomarkers of amyloid, most of the CSF tau measures (with the exception of pT205/T205, pT175/T175, pS199/S199 and pS202/S202) and CDR-SB.